RecruitingPhase 2NCT05672251

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Sponsor

City of Hope Medical Center

Enrollment

36 participants

Start Date

Jan 2, 2024

Study Type

INTERVENTIONAL

Conditions

Recurrent Transformed Chronic Lymphocytic Leukemia Refractory Transformed Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma Recurrent Grade 3b Follicular Lymphoma Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma Refractory Grade 3b Follicular Lymphoma Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Summary

This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, loncastuximab, linked to a toxic agent called tesirine. Loncastuximab attaches to anti-CD19 cancer cells in a targeted way and delivers tesirine to kill them. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving loncastuximab tesirine with mosunetuzumab may help treat patients with relapsed or refractory diffuse large B-cell lymphoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a combination of two drugs — loncastuximab tesirine (an antibody that delivers chemotherapy directly to lymphoma cells) and mosunetuzumab (a bispecific antibody that helps the immune system attack lymphoma cells) — in patients with diffuse large B-cell lymphoma (DLBCL) that has come back or is not responding to prior treatments. **You may be eligible if...** - You are 18 or older - You have confirmed relapsed or refractory DLBCL - Your general health is adequate (ECOG 0–2) - You are willing to provide a tumor biopsy sample **You may NOT be eligible if...** - You have uncontrolled active infections or severe organ damage - You have untreated central nervous system lymphoma - You are pregnant or breastfeeding - You have received prior treatment with either of these specific drugs Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.